Analysis
Kevin Weil, a former OpenAI science lead, has raised $215 million at an $865 million valuation for his new startup, Warp Sciences, which trains robots to automate lab work for drug discovery. Weil announced the round and the company's emergence from stealth on X on October 22, and TechCrunch confirmed the terms: Lightspeed led the round, with IVP, Premji Invest and Lux Capital participating.
The company trains robots to make and test the chemical compounds researchers identify as promising drug candidates. Human chemists wear cameras and sensor-equipped gloves to teach the robots lab techniques, with the goal of running the equipment around the clock rather than on human shifts. Weil has framed the pitch around reshoring work that biotech companies currently outsource to contractors in China, such as WuXi AppTec, back onto US soil.
How the round came together
Warp Sciences didn't appear from nowhere. In August 2026, Dealroom reported, citing Business Insider, that Weil was in talks to raise funding for a then-unnamed, still-stealth AI science startup at a valuation of at least $750 million, with terms not yet finalized.
Two months later, the company has a name, a public launch and a larger, closed round. The $215 million raised and $865 million valuation confirmed this week mark a bump from the valuation floor reported over the summer. That gap between a stealth rumor and a confirmed close is typical for mega-rounds assembled by repeat, well-connected founders -- Weil spent years at OpenAI before this, and before that held senior product roles at Twitter and Instagram.
Competitive landscape
Warp Sciences enters a crowded and well-capitalized "physical AI" and lab-automation category. Emerald Cloud Lab and Strateos have pursued remote, automated wet-lab infrastructure for years; Recursion Pharmaceuticals and Insitro use AI and automation to speed up drug discovery pipelines at public-company scale; and robotics labs from Google DeepMind's Isomorphic Labs to smaller software-focused startups are all racing to compress the time between identifying a candidate molecule and testing it. What differentiates Warp Sciences, per the TechCrunch report, is its narrower bet on robotic execution of the physical bench work itself rather than the computational discovery step upstream.
The numbers in context
An $865 million valuation for a company with no disclosed revenue and an unspecified headcount is a steep multiple on ambition. For comparison, Recursion Pharmaceuticals trades as a public company with a market cap that has fluctuated well below $2 billion despite a decade of operating history and multiple drug programs in clinical trials. Warp Sciences is being valued at a meaningful fraction of that figure on day one of its public existence, a reflection of how much investor enthusiasm has shifted from software-only AI bets toward startups that combine AI with physical infrastructure -- robotics, biotech, energy -- a category Pulse has tracked across funding rounds involving OpenAI alumni this year.
What it means for founders and GPs
For founders building in physical AI, the Warp Sciences round is a signal that marquee-name founders can still raise at software-style multiples even when the product is capital-intensive and hardware-dependent. For GPs, it raises the bar for other robotics and lab-automation pitches crossing their desks this quarter -- expect comparisons to Warp Sciences' valuation mark in the next twelve months of term sheets.
What the headline number misses is execution risk. Training robots to replicate the dexterity and judgment of a trained bench chemist is a notoriously hard robotics problem that companies with far longer runways, including Emerald Cloud Lab, have spent years working through without fully automating a lab end to end. Capital alone doesn't solve the manipulation and calibration challenges that have slowed this category before; Warp Sciences will need to show a working throughput number, not just a funding announcement, before the thesis is proven.
Weil's team has not disclosed its headcount, a target launch date for commercial lab services, or named pharmaceutical or biotech customers. Those gaps are worth watching as the company moves from a funding announcement to an operating business.